Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864541 | 0.88 | PIK3CD (0.57) | PIK3CDPIK3CGLMNAHSD17B10 | |
| SCHEMBL864806 | 0.87 | PIK3CD (0.42) | PIK3CDPIK3CGEGFRPIK3CAPIK3R1 | |
| SCHEMBL864807 | 0.87 | PIK3CD (0.42) | PIK3CDPIK3CGEGFRPIK3CAPIK3R1 | |
| SCHEMBL23891075 | 0.81 | PIK3CD (0.53) | PIK3CDPIK3CGEGFRPIK3CAPIK3CB | |
| SCHEMBL10285793 | 0.80 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CAPIK3R1AURKA | |
| SCHEMBL13853392 | 0.80 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CAPIK3R1AURKA | |
| SCHEMBL788764 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CG | |
| SCHEMBL863647 | 0.79 | PIK3CD (0.50) | PIK3CDPIK3CGEGFRPIK3CAPIK3R1 | |
| SCHEMBL863646 | 0.79 | PIK3CD (0.50) | PIK3CDPIK3CGEGFRPIK3CAPIK3R1 | |
| SCHEMBL864955 | 0.76 | PIK3CD (0.46) | PIK3CDPIK3CGEGFRPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885PIK3CG 21/4885EGFR 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.